These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 36973504)

  • 1. Effect of sclerostin inactivation in a mouse model of severe dominant osteogenesis imperfecta.
    Marulanda J; Tauer JT; Boraschi-Diaz I; Bardai G; Rauch F
    Sci Rep; 2023 Mar; 13(1):5010. PubMed ID: 36973504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of sclerostin antibody treatment in a mouse model of severe osteogenesis imperfecta.
    Roschger A; Roschger P; Keplingter P; Klaushofer K; Abdullah S; Kneissel M; Rauch F
    Bone; 2014 Sep; 66():182-8. PubMed ID: 24953712
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sclerostin-Antibody Treatment Decreases Fracture Rates in Axial Skeleton and Improves the Skeletal Phenotype in Growing oim/oim Mice.
    Cardinal M; Dessain A; Roels T; Lafont S; Ominsky MS; Devogelaer JP; Chappard D; Mabilleau G; Ammann P; Nyssen-Behets C; Manicourt DH
    Calcif Tissue Int; 2020 May; 106(5):494-508. PubMed ID: 32025752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Anti-TGF-β Treatment in a Mouse Model of Severe Osteogenesis Imperfecta.
    Tauer JT; Abdullah S; Rauch F
    J Bone Miner Res; 2019 Feb; 34(2):207-214. PubMed ID: 30357929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tendon properties in a mouse model of severe osteogenesis imperfecta.
    Sinkam L; Boraschi-Diaz I; Svensson RB; Kjaer M; Komarova SV; Bergeron R; Rauch F; Veilleux LN
    Connect Tissue Res; 2023 May; 64(3):285-293. PubMed ID: 36576243
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First mouse model for combined osteogenesis imperfecta and Ehlers-Danlos syndrome.
    Chen F; Guo R; Itoh S; Moreno L; Rosenthal E; Zappitelli T; Zirngibl RA; Flenniken A; Cole W; Grynpas M; Osborne LR; Vogel W; Adamson L; Rossant J; Aubin JE
    J Bone Miner Res; 2014 Jun; 29(6):1412-23. PubMed ID: 24443344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adult Brtl/+ mouse model of osteogenesis imperfecta demonstrates anabolic response to sclerostin antibody treatment with increased bone mass and strength.
    Sinder BP; White LE; Salemi JD; Ominsky MS; Caird MS; Marini JC; Kozloff KM
    Osteoporos Int; 2014 Aug; 25(8):2097-107. PubMed ID: 24803333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low Dose of Bisphosphonate Enhances Sclerostin Antibody-Induced Trabecular Bone Mass Gains in Brtl/+ Osteogenesis Imperfecta Mouse Model.
    Olvera D; Stolzenfeld R; Marini JC; Caird MS; Kozloff KM
    J Bone Miner Res; 2018 Jul; 33(7):1272-1282. PubMed ID: 29544018
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum Sclerostin Levels in Adults With Osteogenesis Imperfecta: Comparison With Normal Individuals and Response to Teriparatide Therapy.
    Nicol L; Wang Y; Smith R; Sloan J; Nagamani SC; Shapiro J; Lee B; Orwoll E
    J Bone Miner Res; 2018 Feb; 33(2):307-315. PubMed ID: 29044725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel ActRIIB ligand trap increases muscle mass and improves bone geometry in a mouse model of severe osteogenesis imperfecta.
    Tauer JT; Rauch F
    Bone; 2019 Nov; 128():115036. PubMed ID: 31419601
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of treatment with a bone-targeted prostaglandin E2 receptor 4 agonist C3 (Mes-1007) in a mouse model of severe osteogenesis imperfecta.
    Boraschi-Diaz I; Chen G; Polak-Nachumow J; Young RN; Rauch F
    Bone; 2021 Apr; 145():115867. PubMed ID: 33524637
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced Wnt signaling improves bone mass and strength, but not brittleness, in the Col1a1(+/mov13) mouse model of type I Osteogenesis Imperfecta.
    Jacobsen CM; Schwartz MA; Roberts HJ; Lim KE; Spevak L; Boskey AL; Zurakowski D; Robling AG; Warman ML
    Bone; 2016 Sep; 90():127-32. PubMed ID: 27297606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sclerostin antibody reduces long bone fractures in the oim/oim model of osteogenesis imperfecta.
    Cardinal M; Tys J; Roels T; Lafont S; Ominsky MS; Devogelaer JP; Chappard D; Mabilleau G; Ammann P; Nyssen-Behets C; Manicourt DH
    Bone; 2019 Jul; 124():137-147. PubMed ID: 31051315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength.
    Li X; Ominsky MS; Niu QT; Sun N; Daugherty B; D'Agostin D; Kurahara C; Gao Y; Cao J; Gong J; Asuncion F; Barrero M; Warmington K; Dwyer D; Stolina M; Morony S; Sarosi I; Kostenuik PJ; Lacey DL; Simonet WS; Ke HZ; Paszty C
    J Bone Miner Res; 2008 Jun; 23(6):860-9. PubMed ID: 18269310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapidly growing Brtl/+ mouse model of osteogenesis imperfecta improves bone mass and strength with sclerostin antibody treatment.
    Sinder BP; Salemi JD; Ominsky MS; Caird MS; Marini JC; Kozloff KM
    Bone; 2015 Feb; 71():115-23. PubMed ID: 25445450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sclerostin inhibition reverses skeletal fragility in an Lrp5-deficient mouse model of OPPG syndrome.
    Kedlaya R; Veera S; Horan DJ; Moss RE; Ayturk UM; Jacobsen CM; Bowen ME; Paszty C; Warman ML; Robling AG
    Sci Transl Med; 2013 Nov; 5(211):211ra158. PubMed ID: 24225945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Calvaria Bone Transcriptome in Mouse Models of Osteogenesis Imperfecta.
    Moffatt P; Boraschi-Diaz I; Marulanda J; Bardai G; Rauch F
    Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34069814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Craniofacial and Dental Defects in the Col1a1Jrt/+ Mouse Model of Osteogenesis Imperfecta.
    Eimar H; Tamimi F; Retrouvey JM; Rauch F; Aubin JE; McKee MD
    J Dent Res; 2016 Jul; 95(7):761-8. PubMed ID: 26951553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sclerostin antibody improves skeletal parameters in a Brtl/+ mouse model of osteogenesis imperfecta.
    Sinder BP; Eddy MM; Ominsky MS; Caird MS; Marini JC; Kozloff KM
    J Bone Miner Res; 2013 Jan; 28(1):73-80. PubMed ID: 22836659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted postnatal knockout of Sclerostin using a bone-targeted adeno-associated viral vector increases bone anabolism and decreases canalicular density.
    O'Donohue AK; Xiao Y; Lee LR; Schofield T; Cheng TL; Munns CF; Baldock PA; Schindeler A
    Bone; 2023 Feb; 167():116636. PubMed ID: 36462771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.